Table 3.
Univariate and multivariate analysis of overall survival (n=22).
| Variable | Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| B | Exp (B) (95% CI) | P | B | Exp (B) (95% CI) | P | |||
| LDH, U/L | -1.196 | 0.302 (0.093-0.987) | 0.047 | -5.740 | 0.003 (0-0.788) | 0.041 | ||
| CEA, ng/ml | -1.743 | 0.175 (0.049-0.629) | 0.008 | -9.153 | 0 (0-0.599) | 0.038 | ||
| Metastatic sites involved | 1.403 | 4.069 (1.364-12.138) | 0.012 | 3.058 | 21.277 (0.555-815.122) | 0.100 | ||
| Histological type | 3.429 | 30.854 (3.106-306.456) | 0.003 | 28.994 | 3.907E+12 (0-9.18E+48) | 0.856 | ||
| Differentiation | -0.497 | 0.608 (0.182-2.036) | 0.420 | 5.141 | 170.811 (0.072-403150.683) | 0.195 | ||
| Mean VAF | 1.269 | 3.559 (0.790-16.023) | 0.098 | 1.791 | 5.994 (0.174-206.541) | 0.321 | ||
| Site of primary lesion | -0.552 | 0.576 (0.157-2.118) | 0.406 | -5.162 | 0.006 (0-0.933) | 0.047 | ||
| Primary tumor resection | -0.091 | 0.913 (0.39-2.618) | 0.886 | 2.795 | 16.365 (0.569-470.439) | 0.103 | ||
| RAS status at baseline | 2.044 | 7.721 (2.120-28.124) | 0.002 | -11.995 | 0 (0-2.945) | 0.072 | ||
LDH, lactate dehydrogenase; CEA, carcinoembryonic antigen.